Brief: Adc Therapeutics SA - SOBI Expects To Commence Launching Zynlonta Upon Completion Of The Marketing Authorization Transfer

Adc Therapeutics

21/12/2022 21:15

Dec 21 (Reuters) - ADC Therapeutics SA  ADCT.N :
    * EU HAS GRANTED CONDITIONAL MARKETING AUTHORIZATION FOR THE
USE
OF ZYNLONTA FOR THE TREATMENT OF RELAPSED OR REFRACTORY DIFFUSE
LARGE B-CELL LYMPHOMA
    * ADC THERAPEUTICS SA - SOBI EXPECTS TO COMMENCE LAUNCHING
ZYNLONTA UPON COMPLETION OF THE MARKETING AUTHORIZATION TRANSFER

Further company coverage:  ADCT.N 
 ((Reuters.Briefs@thomsonreuters.com;))